US pharma major AbbVie and China’s RemeGen today announced an exclusive licensing agreement for the development, ...

In an extensive review, researchers explore ZBP1-mediated programmed cell death and its potential as a therapeutic target for systemic diseases Programmed cell death, or PCD, is an actively regulated ...

AbbVie & RemeGen enter exclusive licensing agreement to develop novel bispecific antibody for advanced solid tumours: North Chicago, Illinois Tuesday, January 13, 2026, 14:00 Hrs ...

In the fight against disease, programmed cell death – also known as apoptosis – is a key protective function of the body. It breaks down cells that are damaged or have undergone dangerous changes.

Immune checkpoint inhibitors (ICIs), including antibodies against the programmed cell death protein 1/ligand 1 (PD-1/L1) ...

The field of immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), particularly ...